Antivirals and Vaccines
Funding
Conflicts of Interest
References
- Wallis, R.S.; O’Garra, A.; Sher, A.; Wack, A. Host-directed immunotherapy of viral and bacterial infections: Past, present and future. Nat. Rev. Immunol. 2023, 23, 121–133. [Google Scholar] [CrossRef]
- Adalja, A.; Inglesby, T. Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool. Expert Rev. Anti Infect. Ther. 2019, 17, 467–470. [Google Scholar] [CrossRef] [Green Version]
- Zakaria, M.K.; Carletti, T.; Marcello, A. Cellular Targets for the Treatment of Flavivirus Infections. Front. Cell. Infect. Microbiol. 2018, 8, 398. [Google Scholar] [CrossRef]
- Setz, C.; Grosse, M.; Auth, J.; Froba, M.; Rauch, P.; Bausch, A.; Wright, M.; Schubert, U. Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern. Int. J. Mol. Sci. 2022, 23, 6830. [Google Scholar] [CrossRef]
- Choudhary, S.; Sharma, K.; Silakari, O. The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options. Microb. Pathog. 2021, 150, 104673. [Google Scholar] [CrossRef]
- Thaler, M.; Salgado-Benvindo, C.; Leijs, A.; Tas, A.; Ninaber, D.K.; Arbiser, J.L.; Snijder, E.J.; van Hemert, M.J. R-Propranolol Has Broad-Spectrum Anti-Coronavirus Activity and Suppresses Factors Involved in Pathogenic Angiogenesis. Int. J. Mol. Sci. 2023, 24, 4588. [Google Scholar] [CrossRef]
- Tan, X.; Guo, S.; Wang, C. Propranolol in the Treatment of Infantile Hemangiomas. Clin. Cosmet. Investig. Dermatol. 2021, 14, 1155–1163. [Google Scholar] [CrossRef]
- Ackermann, M.; Mentzer, S.J.; Kolb, M.; Jonigk, D. Inflammation and intussusceptive angiogenesis in COVID-19: Everything in and out of flow. Eur. Respir. J. 2020, 56, 2003147. [Google Scholar] [CrossRef]
- Subedi, S.; Koirala, S.; Chai, L. COVID-19 in Farm Animals: Host Susceptibility and Prevention Strategies. Animals 2021, 11, 640. [Google Scholar] [CrossRef]
- Edwards, C.E.; Yount, B.L.; Graham, R.L.; Leist, S.R.; Hou, Y.J.; Dinnon, K.H., 3rd; Sims, A.C.; Swanstrom, J.; Gully, K.; Scobey, T.D.; et al. Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection. Proc. Natl. Acad. Sci. USA 2020, 117, 26915–26925. [Google Scholar] [CrossRef]
- Luo, Y.; Chen, Y.; Geng, R.; Li, B.; Chen, J.; Zhao, K.; Zheng, X.S.; Zhang, W.; Zhou, P.; Yang, X.L.; et al. Broad Cell Tropism of SADS-CoV In Vitro Implies Its Potential Cross-Species Infection Risk. Virol. Sin. 2021, 36, 559–563. [Google Scholar] [CrossRef]
- Chen, Y.; You, Y.; Wang, S.; Jiang, L.; Tian, L.; Zhu, S.; An, X.; Song, L.; Tong, Y.; Fan, H. Antiviral Drugs Screening for Swine Acute Diarrhea Syndrome Coronavirus. Int. J. Mol. Sci. 2022, 23, 11250. [Google Scholar] [CrossRef]
- Jang, Y.; Shin, J.S.; Lee, M.K.; Jung, E.; An, T.; Kim, U.I.; Kim, K.; Kim, M. Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2. Int. J. Mol. Sci. 2021, 22, 1581. [Google Scholar] [CrossRef]
- Kato, F.; Matsuyama, S.; Kawase, M.; Hishiki, T.; Katoh, H.; Takeda, M. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2. Microbiol. Immunol. 2020, 64, 635–639. [Google Scholar] [CrossRef]
- Gendrot, M.; Andreani, J.; Duflot, I.; Boxberger, M.; Le Bideau, M.; Mosnier, J.; Jardot, P.; Fonta, I.; Rolland, C.; Bogreau, H.; et al. Methylene blue inhibits replication of SARS-CoV-2 in vitro. Int. J. Antimicrob. Agents 2020, 56, 106202. [Google Scholar] [CrossRef]
- Fan, H.; He, S.T.; Han, P.; Hong, B.; Liu, K.; Li, M.; Wang, S.; Tong, Y. Cepharanthine: A Promising Old Drug against SARS-CoV-2. Adv. Biol. 2022, 6, e2200148. [Google Scholar] [CrossRef]
- Sajgure, A.; Kulkarni, A.; Joshi, A.; Sajgure, V.; Pathak, V.; Melinkeri, R.; Pathak, S.; Agrawal, S.; Naik, M.; Rajurkar, M.; et al. Safety and efficacy of mycophenolate in COVID-19: A nonrandomised prospective study in western India. Lancet Reg. Health Southeast Asia 2023, 11, 100154. [Google Scholar] [CrossRef]
- Dabholkar, N.; Gorantla, S.; Dubey, S.K.; Alexander, A.; Taliyan, R.; Singhvi, G. Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations. Biomed. Pharmacother. 2021, 142, 112023. [Google Scholar] [CrossRef]
- Wedekind, S.I.S.; Shenker, N.S. Antiviral Properties of Human Milk. Microorganisms 2021, 9, 715. [Google Scholar] [CrossRef]
- Laucirica, D.R.; Triantis, V.; Schoemaker, R.; Estes, M.K.; Ramani, S. Milk Oligosaccharides Inhibit Human Rotavirus Infectivity in MA104 Cells. J. Nutr. 2017, 147, 1709–1714. [Google Scholar] [CrossRef] [Green Version]
- Ramani, S.; Stewart, C.J.; Laucirica, D.R.; Ajami, N.J.; Robertson, B.; Autran, C.A.; Shinge, D.; Rani, S.; Anandan, S.; Hu, L.; et al. Human milk oligosaccharides, milk microbiome and infant gut microbiome modulate neonatal rotavirus infection. Nat. Commun. 2018, 9, 5010. [Google Scholar] [CrossRef] [Green Version]
- Hong, P.; Ninonuevo, M.R.; Lee, B.; Lebrilla, C.; Bode, L. Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN). Br. J. Nutr. 2009, 101, 482–486. [Google Scholar] [CrossRef] [Green Version]
- Lou, F.; Hu, R.; Chen, Y.; Li, M.; An, X.; Song, L.; Tong, Y.; Fan, H. 2’-Fucosyllactose Inhibits Coxsackievirus Class A Type 9 Infection by Blocking Virus Attachment and Internalisation. Int. J. Mol. Sci. 2022, 23, 13727. [Google Scholar] [CrossRef]
- Marjomäki, V.; Turkki, P.; Huttunen, M. Infectious Entry Pathway of Enterovirus B Species. Viruses 2015, 7, 6387–6399. [Google Scholar] [CrossRef]
- Baggen, J.; Thibaut, H.J.; Strating, J.R.P.M.; van Kuppeveld, F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 2018, 16, 368–381. [Google Scholar] [CrossRef]
- van Tienen, C.; van der Loeff, M.S. Epidemiology of HIV-2 Infection in West Africa. In Encyclopedia of AIDS; Hope, T.J., Stevenson, M., Richman, D., Eds.; Springer: New York, NY, USA, 2016; pp. 1–11. [Google Scholar]
- UNAIDS. Fact Sheet—Latest Statistics on the Status of the AIDS Epidemic; UNAIDS: Geneve, Switzerland, 2016. [Google Scholar]
- Esbjornsson, J.; Mansson, F.; Kvist, A.; da Silva, Z.J.; Andersson, S.; Fenyo, E.M.; Isberg, P.E.; Biague, A.J.; Lindman, J.; Palm, A.A.; et al. Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: A prospective open cohort study. Lancet HIV 2018, 6, e25–e31. [Google Scholar] [CrossRef] [PubMed]
- Matheron, S.; Pueyo, S.; Damond, F.; Simon, F.; Lepretre, A.; Campa, P.; Salamon, R.; Chene, G.; Brun-Vezinet, F. Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort. AIDS 2003, 17, 2593–2601. [Google Scholar] [CrossRef] [PubMed]
- de Mendoza, C.; Requena, S.; Caballero, E.; Cabezas, T.; Penaranda, M.; Amengual, M.J.; Saez, A.; Lozano, A.B.; Ramos, J.M.; Soriano, V. Antiretroviral treatment of HIV-2 infection. Future Virol. 2017, 12, 461–472. [Google Scholar] [CrossRef]
- Lin, P.F.; Blair, W.; Wang, T.; Spicer, T.; Guo, Q.; Zhou, N.; Gong, Y.F.; Wang, H.G.; Rose, R.; Yamanaka, G.; et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. USA 2003, 100, 11013–11018. [Google Scholar] [CrossRef] [Green Version]
- Meanwell, N.A.; Krystal, M.R.; Nowicka-Sans, B.; Langley, D.R.; Conlon, D.A.; Eastgate, M.D.; Grasela, D.M.; Timmins, P.; Wang, T.; Kadow, J.F. Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir. J. Med. Chem. 2018, 61, 62–80. [Google Scholar] [CrossRef]
- Wang, T.; Zhang, Z.; Wallace, O.B.; Deshpande, M.; Fang, H.; Yang, Z.; Zadjura, L.M.; Tweedie, D.L.; Huang, S.; Zhao, F.; et al. Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): A novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. 2003, 46, 4236–4239. [Google Scholar] [CrossRef]
- Sarfo, F.S.; Bibby, D.F.; Schwab, U.; Appiah, L.T.; Clark, D.A.; Collini, P.; Phillips, R.; Green, I.; Dittmar, M.T.; Chadwick, D.R. Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: A retrospective study. J. Antimicrob. Chemother. 2009, 64, 667–669. [Google Scholar] [CrossRef] [Green Version]
- Drylewicz, J.; Eholie, S.; Maiga, M.; Zannou, D.M.; Sow, P.S.; Ekouevi, D.K.; Peterson, K.; Bissagnene, E.; Dabis, F.; Thiebaut, R.; et al. First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration. AIDS 2010, 24, 1043–1050. [Google Scholar] [CrossRef] [Green Version]
- Ntemgwa, M.L.; d’Aquin Toni, T.; Brenner, B.G.; Camacho, R.J.; Wainberg, M.A. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob. Agents Chemother. 2009, 53, 3611–3619. [Google Scholar] [CrossRef] [Green Version]
- Tzou, P.L.; Descamps, D.; Rhee, S.Y.; Raugi, D.N.; Charpentier, C.; Taveira, N.; Smith, R.A.; Soriano, V.; de Mendoza, C.; Holmes, S.P.; et al. Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2. J. Infect. Dis. 2020, 221, 1962–1972. [Google Scholar] [CrossRef]
- Moranguinho, I.; Taveira, N.; Bartolo, I. Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds. Int. J. Mol. Sci. 2023, 24, 5905. [Google Scholar] [CrossRef]
- Khare, B.; Kuhn, R.J. The Japanese Encephalitis Antigenic Complex Viruses: From Structure to Immunity. Viruses 2022, 14, 2213. [Google Scholar] [CrossRef]
- Schuh, A.J.; Ward, M.J.; Leigh Brown, A.J.; Barrett, A.D. Dynamics of the emergence and establishment of a newly dominant genotype of Japanese encephalitis virus throughout Asia. J. Virol. 2014, 88, 4522–4532. [Google Scholar] [CrossRef] [Green Version]
- Adamson, C.S.; Chibale, K.; Goss, R.J.M.; Jaspars, M.; Newman, D.J.; Dorrington, R.A. Antiviral drug discovery: Preparing for the next pandemic. Chem. Soc. Rev. 2021, 50, 3647–3655. [Google Scholar] [CrossRef]
- Li, C.; Chen, X.; Hu, J.; Jiang, D.; Cai, D.; Li, Y. A Recombinant Genotype I Japanese Encephalitis Virus Expressing a Gaussia Luciferase Gene for Antiviral Drug Screening Assay and Neutralizing Antibodies Detection. Int. J. Mol. Sci. 2022, 23, 15548. [Google Scholar] [CrossRef]
- Tannous, B.A.; Kim, D.E.; Fernandez, J.L.; Weissleder, R.; Breakefield, X.O. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol. Ther. 2005, 11, 435–443. [Google Scholar] [CrossRef]
- Anderson, C.R.; Downs, W.G.; Wattley, G.H.; Ahin, N.W.; Reese, A.A. Mayaro virus: A new human disease agent. II. Isolation from blood of patients in Trinidad, B.W.I. Am. J. Trop. Med. Hyg. 1957, 6, 1012–1016. [Google Scholar] [CrossRef]
- Levi, L.I.; Vignuzzi, M. Arthritogenic Alphaviruses: A Worldwide Emerging Threat? Microorganisms 2019, 7, 133. [Google Scholar] [CrossRef] [Green Version]
- Diagne, C.T.; Bengue, M.; Choumet, V.; Hamel, R.; Pompon, J.; Missé, D. Mayaro Virus Pathogenesis and Transmission Mechanisms. Pathogens 2020, 9, 738. [Google Scholar] [CrossRef]
- Kim, Y.C.; Lucke, A.C.; Lopez-Camacho, C.; Kummerer, B.M.; Reyes-Sandoval, A. Development of Viral-Vectored Vaccines and Virus Replicon Particle-Based Neutralisation Assay against Mayaro Virus. Int. J. Mol. Sci. 2022, 23, 4105. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Taveira, N. Antivirals and Vaccines. Int. J. Mol. Sci. 2023, 24, 10315. https://doi.org/10.3390/ijms241210315
Taveira N. Antivirals and Vaccines. International Journal of Molecular Sciences. 2023; 24(12):10315. https://doi.org/10.3390/ijms241210315
Chicago/Turabian StyleTaveira, Nuno. 2023. "Antivirals and Vaccines" International Journal of Molecular Sciences 24, no. 12: 10315. https://doi.org/10.3390/ijms241210315